Optimization and Investigation of Cruentaren A analogs
$357,067R01FY2017CANIH
University Of Notre Dame, Notre Dame IN
Investigators
Linked publications & trials
Paper 39153203Paper 38516588Paper 36867738Paper 34353633Paper 33958760Paper 33904516Paper 32942072Paper 32718802Paper 32249628Paper 31793427Paper 31561992Paper 31371177Paper 29753460Paper 29488071Paper 29121598Paper 28361210
Abstract
Abstract The development of new methods to treat cancer is greatly needed. In this application, we have identified a macrocyclic small molecule that exhibits high differential selectivity for cancer cells vs. normal cells and aim to develop more simplified analogs of this molecule in an effort to maximize efficiency as well as to decrease the overall number of steps, which will likely lead to clinically useful molecules for the treatment of cancer. In addition, we aim to interrogate the activity manifested by these compounds in both cellular and animal models of cancer, with the goal of providing preclinical data to support the use of such compounds for translational development.
View original record on NIH RePORTER →